Viewing Study NCT00004329



Ignite Creation Date: 2024-05-05 @ 11:22 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004329
Status: COMPLETED
Last Update Posted: 2005-06-24
First Post: 1999-10-18

Brief Title: Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy
Sponsor: National Center for Research Resources NCRR
Organization: National Center for Research Resources NCRR

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2003-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OBJECTIVES I Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist clonidine and the antagonist yohimbine of the alpha-2 adrenergic receptor in 6 patients with regional lipoatrophy and in 6 controls

II Determine the full sequence of the alpha-2 adrenergic receptor structural gene in genomic DNA from peripheral blood leukocytes
Detailed Description: PROTOCOL OUTLINE Antihypertensives are held beginning 3 days before the first study day

An oral challenge is administered as follows clonidine on day 1 yohimbine on day 2 The order of administration is reversed in alternate subjects

Timed measurements of norepinephrine glycerol and free fatty acids follow each challenge Structural gene sequencing is evaluated for each participant

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
UTMB-437 None None None